Skip to Content
Merck
  • The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease: a meta-analysis.

The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease: a meta-analysis.

Neuromolecular medicine (2014-02-06)
Wenjin Wei, Xiupeng Xu, Hailin Li, Yaxuan Zhang, Dongfeng Han, Yingyi Wang, Wei Yan, Xiefeng Wang, Junxia Zhang, Ning Liu, Yongping You
ABSTRACT

Previous studies have reported an association between human sirtuins' single-nucleotide polymorphisms (SNPs) and Alzheimer's disease (AD) susceptibility in the apolipoprotein E (APOE) ε4-negative population, although the findings are inconsistent. To obtain a more precise estimation of this relationship, we conducted a meta-analysis to assess the association between the rs10410544 C/T polymorphism of SIRT2 and the risk of AD with APOE ε4 status. We searched all relevant PubMed publications and included three studies in our meta-analysis involving a total of 1,794 patients and 2,054 control subjects. Odds ratios (ORs) with 95% confidence intervals (CIs) were employed to evaluate the association of the SIRT2 SNP with AD susceptibility, and we analyzed the extracted data stratified by the APOE ε4-carrying status. Overall, the results show that the SIRT2 SNP is associated with human AD risk in the comparison models (T vs. C: OR 1.140, 95% CI 1.034-1.258; TC vs. CC: OR 1.178, 95% CI 1.019-1.361; TT + TC vs. CC: OR 1.197, 95% CI 1.043-1.373). In the stratified analyses, the European population had a significantly increased risk of AD (T vs. C: OR 1.110, 95% CI 1.002-1.229), and we also observed a significant association in the APOE ε4-negative population (T vs. C: OR 1.165, 95% CI 1.025-1.324; TT + TC vs. CC: OR 1.222, 95% CI 1.022-1.461). This meta-analysis indicates that the presence of the SIRT2 SNP with APOE ε4-negative status contributes to the development of AD in humans Epidemiological studies of larger sample sizes are warranted to confirm this hypothesis.